Criteria to Assess the Predictive and Clinical Utility of Cardiovascular Disease
Published: February 11, 2026
- This Scientific Statement provides an updated framework for the critical appraisal of the predictive and clinical utility of novel biomarkers, models, and tools and builds upon the previously published AHA Scientific Statement on the “Criteria for Evaluation of Novel Markers of Cardiovascular Risk”.
- This updated Statement reviewed (1) general considerations for Cardiovascular Disease (CVD) risk prediction; (2) statistical assessment of accuracy, precision, and incremental value that considers the current risk model used in clinical practice; (3) clinical utility and (4) additional considerations prior to implementation in practice.
- The intent is to support clinicians, researchers, and policymakers to evaluate current and emerging risk prediction strategies and ultimately improve prevention of CVD in diverse populations.